Cite
HARVARD Citation
Imai, H. et al. (2019). Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors. Thoracic cancer. 10 (12), pp. 2200-2208. [Online].